Publications by authors named "Faraha Brewer"
Article Synopsis
- Vγ9Vδ2 T cell immunotherapy is being explored for its ability to fight various cancers by leveraging its unique cytotoxic properties that don't rely on MHC recognition.
- Researchers have found that the BTN2A1 and BTN3A1 proteins provide the primary activation signal (signal 1) for Vγ9Vδ2 T cells, while the details surrounding the necessary secondary signal (signal 2) needed for full activation remain uncertain.
- In experiments, a BTN2A1/3A1 fusion protein activated Vγ9Vδ2 T cells when combined with costimulatory signals, and it also boosted the cancer-killing ability of these T cells against CD19 lymphoma cells, indicating that tumor cells
We have developed a high-throughput platform to detect the presence of HIV-1 and SIV-specific ADCC-mediating antibody responses. The assay is based on the hydrolysis of a cell-permeable fluorogenic peptide substrate containing a sequence recognized by the serine protease, Granzyme B (GzB). GzB is delivered into target cells by cytotoxic effector cells as a result of antigen (Ag)-specific Ab-Fcγ receptor interactions.
View Article and Find Full Text PDFThe chemokine receptor CXCR4 is expressed in B cells at multiple stages of their development. CXCR4 function in humoral immunity has not been fully investigated. We have generated gene-targeted mice in which CXCR4 can be selectively inactivated in B cells and have shown that it is required for retention of B cell precursors in the bone marrow.
View Article and Find Full Text PDF